 |
FDA Approval Activities for this Drug
GlucaGen [glucagon (rDNA origin) for Injection, Novo Nordisk NDA 20-918/S3 7/11/02 7/15/02
GlucaGen [glucagon (rDNA origin) for injection, SC, IM, or IV injection], Novo Nordisk NDA 20-918 6/22/98 6/24/98 6/24/98
GlucaGen Indications: Treatment of hypoglycemia, and Use as a diagnostic aid.
Glucagon (rDNA origin) for Injection, Eli Lilly NDA 20-928 9/11/98 9/17/98 9/17/98 3/16/99
Glucagon Indications:1) The treatment of severe hypoglycemia, and 2) Use as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. (Patient Information- 9/24/98) Glucagon (rDNA origin) for Injection, RxEli Lilly GlucaGen [glucagon (rDNA origin) Injection, Novo Nordisk Pharmaceuticals | GlucaGen (glucagon [rDNA origin] injection), Novo Nordisk, Package Change
For the most up-to-date approval information, please locate this API using the drug index.
|